Burda Principal Investments’ Post

John R. Hodge, Managing Partner Americas, discusses Private Equity, Venture Capital Markets and MedTech in this video interview series. In this clip, John outlines how recent advancements in MedTech have affected the Private Equity and Venture Capital Markets on a global scale.  Bill Niland Tony Lowman ReGelTec, Inc. Watch more here: https://lnkd.in/ey8VpJef #MedTech #VentureCapital #PrivateEquity

Great quarter to be in SD Biotech: "In San Diego, startup funding for the second quarter surpassed $1 billion for the fifth consecutive year, driven by dozens of tech and life science venture capital fundings. San Diego saw roughly 42 deals in Q2 including four startups raising $100 million, known as mega-deals." Top five largest bio deals: Endeavor BioMedicines: a Solana Beach-based biotech raised $132 million Alterome Therapeutics, Inc: an early-stage biotech raised $132 million. Enlaza Therapeutics: a La Jolla-based company raised $100 million. Bright Peak Therapeutics: a Del Mar-based biotech raised $90 million. Aardvark Therapeutics: a UTC-based biotech raised $85 million.

Rival tech businesses to merge These tech company chief executives are planning to merge their rival venture capital-backed businesses to pool resources and accelerate international expansion. Read more about this, and much more about venture capital and private equity, at: https://lnkd.in/gE-aPUTb #venturecapital #privateequity #technology

While listening to Siemens' female CEO during the Global Corp Venture Innovations Summit in California this week, I realized that LoftyInc's investing strategies have been scientifically tested and validated. As entrepreneurs and angel investors, our team has evaluated thousands of potential options, gauged risks logically, tested hypotheses objectively, and retested successful strategies consistently. Testing strategies with our own money, before we invest the capital of others-- this is the acumen LoftyInc partners bring to each deal. 

Buckle Up: Emerging Trends in New Mobility Worldwide In this http://spr.ly/6043V1i5x Audio Interview "Buckle Up: Emerging Trends in New Mobility Worldwide" Ron Hesse speaks with Sam Baker, Managing Partner of MobilityFund, a venture capital firm. http://spr.ly/6049V1i5N #Automotive #AutomotiveTechnology #IndustryNews

Buckle Up: Emerging Trends in New Mobility Worldwide In this http://spr.ly/6045V1i5L Audio Interview "Buckle Up: Emerging Trends in New Mobility Worldwide" Ron Hesse speaks with Sam Baker, Managing Partner of MobilityFund, a venture capital firm. http://spr.ly/6041V1i5f #Automotive #AutomotiveTechnology #IndustryNews

AQUATY is changing the game for venture capital, raising €2.3M pre-seed to reduce barriers. Imagine this: Venture capital investments as easy as buying stocks. AQUATY's platform is making it happen. With AI-driven transparency, digital investment processes, and seamless ESOP management, it's a new era for private markets. Robert Jeggle (geb. Menzel), Andy Lenz Alexander Grimm, Marten Hausen Three Reasons to Celebrate: 1. Access: Small ticket sizes from €1,000. 2. Efficiency: 10x faster transactions. 3. Growth: Expanding with Alexander Grimm’s expertise. AQUATY is here to democratize early-stage investments and fuel innovation. Would you invest with just €1,000? https://lnkd.in/dKFwt7VN #VentureCapital #Innovation #InvestmentOpportunity #MondayFunding

I had a great time at Venture Summit West. I met some fantastic folks, saw many amazing presentations of technology that blew me away, and sat in on several insightful panels. For me there were three key takeaways: 1) no matter how hard the market is right now it's better to be a start up raising at this time rather than a few years ago. 2) There was a fair bit of discussion on the pros/cons of M&A vs. IPO not only for biotechs in the market but also those in the clinic and preclinical development. 3) Corporate investors can be fantastic but that doesn't mean the synergy of technology and visions won't shift as the strategy of the corporate partner changes over time.